Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders. Leveraging a proprietary screening platform, structural biology capabilities and medicinal chemistry expertise, Aardvark has advanced multiple preclinical candidates toward IND-enabling studies. These programs are supported by in vitro and in vivo pharmacology, biomarker development and toxicology assessments conducted at the company’s Cambridge research facilities.

Founded by a team of immunology and drug-development veterans, Aardvark Therapeutics is led by President and CEO Marshall Bolog, Ph.D. The leadership team combines translational pharmacology, clinical development and regulatory affairs expertise to guide the company’s pipeline through preclinical and early clinical stages. Aardvark pursues strategic collaborations with academic institutions and industry partners to enhance its RORγ portfolio and is positioned to advance its therapeutic candidates into human trials while exploring global licensing and development opportunities.

Key Stats

• Today's Range: $5.62 to $6.66
• 50-Day Range: $3.48 to $7.60
• 52-Week Range: $3.35 to $17.94
• Volume: 89,271 shs
• Average Volume: 402,861 shs
• Market Capitalization: $144.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.30
• Consensus Rating: Hold

Aardvark Therapeutics Stock Analysis - MarketRank™

Aardvark Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 312th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Aardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Aardvark Therapeutics has a consensus price target of $16.30, representing about 147.0% upside from its current price of $6.60.

Amount of Analyst Coverage

Aardvark Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.48) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aardvark Therapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aardvark Therapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aardvark Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.62% of the float of Aardvark Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aardvark Therapeutics has a short interest ratio ("days to cover") of 0.96, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aardvark Therapeutics has recently increased by 23.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aardvark Therapeutics does not currently pay a dividend.

Dividend Growth

Aardvark Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Aardvark Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Aardvark Therapeutics this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for AARD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aardvark Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Aardvark Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Aardvark Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/01/2026
• AGM 2026: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $16.30
• High Price Target: $47.00
• Low Price Target: $3.00
• Potential Upside/Downside: +147.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.46
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.71%
• Return on Assets: -56.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.06
• Quick Ratio: 8.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.90 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 21,880,000
• Free Float: 17,989,000
• Market Cap: $144.41 million
• Optionable: N/A
• Beta: 3.93